strategies to optimize heart failure treatment new

Strategies to Optimize Heart Failure Treatment: New Insights and - PowerPoint PPT Presentation

Strategies to Optimize Heart Failure Treatment: New Insights and Challenges Harleen Singh, Pharm.D.,BCPS-AQ Cardiology, BCACP Clinical Associate Professor OSU/OHSU College of Pharmacy Objectives Examine evidence-based guidelines for the

  1. Strategies to Optimize Heart Failure Treatment: New Insights and Challenges Harleen Singh, Pharm.D.,BCPS-AQ Cardiology, BCACP Clinical Associate Professor OSU/OHSU College of Pharmacy

  2. Objectives • Examine evidence-based guidelines for the management of heart failure with reduced ejection fraction, including the role of newer agents • Recognize the challenges associated with up-titration of HF medications • Design individualized therapy to optimize treatment • Describe the key self-care interventions in the management of HF

  3. Disclosures Presenter of this CE have nothing to disclose

  4. GDTM in the Outpatient Setting J Am Coll Cardiol 2018;72:351–66 )

  5. GDTM in HFrEF J Am Coll Cardiol 2018;72:351–66 )

  6. Classification of Heart Failure Classification EF (%) Description Heart failure with ≤40 • Systolic HF reduced ejection fraction • Randomized clinical trials have mainly enrolled (HF r EF) patients with HF r EF, and it is only in these patients that efficacious therapies have been demonstrated to date Heart failure with ≥50 • Diastolic HF preserved ejection Diagnosis of HF p EF is challenging because it is • fraction (HF p EF) largely one of excluding other potential noncardiac causes of symptoms suggestive of HF • To date, efficacious therapies have not been identified HF p EF, borderline 41 - 49 • These patients’ characteristics, treatment patterns, and outcomes appear similar to those with HF p EF HF p EF, improved >40 • Patients with improved or recovery in EF may be clinically distinct from those with persistently preserved or reduced EF • Further research is needed to better characterize these patients

  7. 10 Principles for Successful Treatment of HF Yancy et al. JACC VOL. 71,NO.2,2018

  8. Key: HFrEF Stage C Treatment Class I recommendation Class II recommendation ACEI/ARB AND Beta blocker with diuretic as needed For patients with resting HR ≥ 70, For patients with For persistently For patients For patients with eGFR ≥ 30 on maximally symptomatic stable on persistent volume tolerated beta mL/min/1.72 m2, African ACEI/ARB, overload, K+ <5.0 mEq/dL blocker dose in Americans, NYHA class II-III NYHA class II-IV NYHA class II-IV sinus rhythm, NYHA class III-IV NYHA class II-III Titrate Add Switch Add Add Hydralazine Aldosterone Ivabradine ARNI Diuretics + Isosorbide Antagonist dinitrate Yancy et al. JACC VOL. 71:2 ,2018

  9. Diuretics Loops: • Furosemide • Torsemide ~5% • Bumetanide Thiazides: • Hydrochlorothizide • Chlorthalidone • Chlorthiazide ~25% • Metolazone Aldosterone Antagonists: • Spironolactone • Eplerenone Other K-Sparing: • Amiloride • Triamterene Nat Rev Cardiol. 2015;12(3):184-92.

  10. Diuretics: Place in Therapy HFrEF Stage C Treatment ACEI/ARBs and beta blockers with diuretic as needed For patients with persistent volume overload, NYHA class II-IV Titrate Diuretics Yancy et al. JACC VOL. 71:2 ,2018

  11. Pharmacologic Properties of Loops Property Furosemide Torsemide Bumetanide Relative potency 1x 2x 40x Bioavailability (%) 10 - 100 80 - 100 80 - 100 Oral/IV dosing 2:1 1:1 1:1 Time to onset (min) 60 60 30 - 60 Oral peak serum concentration (h) 1 1 1 -2 Absorption affected by food Yes No Yes Average half-life (h) 2 3.5 1 - 1.5 Duration of effect (h) 6-8 6- 16 4 -6 Decreased kaliuresis No Yes No Am Heart J 2015;169:323-33

  12. Diuretics: Initiation and Titration Diuretics Select initial loop diuretic dose based on: • Diuretic naïve • Renal function • Titrate doses to response over days to weeks • May reduce diuretic doses in the setting of titrating ACEI, ARBs, or ARNI • Monitor: blood pressure, electrolytes, and renal function both after initiation and titration Patients who have received doses of furosemide equivalent to 120 mg twice daily consider: • Changing to a different loop diuretic • Adding a thiazide-like diuretic • Monitor blood pressure, electrolytes, and renal function both after initiation and titration Yancy et al. JACC VOL. 71:2 ,2018

  13. Dose-Response Relationship Ceiling Dose Normal Decreased max response “Steep” part of Heart Failure dose-response curve Elevated diuretic threshold (resistance) Patients with heart failure require a higher serum diuretic concentration to elicit the same diuretic response (diuretic resistance) and have diminished responses to ceiling doses of loop diuretics. J Card Fail. 2014;20(8):611-22

  14. Mechanisms of loop diuretic resistance Nat. Rev. Cardiol. doi:10.1038/nrcardio.2014.215

  15. Metolazone • Metolazone is most commonly prescribed for combination therapy in the U.S. • Retains efficacy in advanced renal failure • However, other thiazides at equipotent doses are likely to have the same synergistic effects Pharmacokinetics Metolazone Hydrochlorothiazide Bioavailability 90 - 95% 65 - 75% Onset of action ~60 min 2 hours Elimination half-life 6- 20 hours 6- 15 hours Duration of action >24 hours 6- 12 hours J Am Coll Cardiol. 2010;56(19):1527-34

  16. Timing of CDT Doses • Pre-dosing of oral metolazone 30-60 min prior to furosemide is common practice – Increased regimen complexity – Inconvenient • No published clinical studies compared pre-dosing to simultaneous dosing • Onset of metolazone is unlikely to be clinically significant with chronic treatment once steady-state is achieved • TD (with longer duration of action) maintains diuresis after short acting LD has worn out J Am Coll Cardiol. 2010;56(19):1527-34

  17. HFrEF: The Building Blocks of Therapy Ivabradine TX Digoxin VAD CRT H-ISDN ICD ARNI Beta blocker MRA ACEI/ARB

  18. Magnitude of Benefits Demonstrated in RCTs NNT for Mortality RR Reduction in RR Reduction in Reduction GDMT HF Mortality (Standardized to Hospitalizations 36 months) ACEI or ARB 17% 26 31% Beta blocker 34% 9 41% Aldosterone 30% 6 35% antagonist Hydralazine/nitrate 43% 7 33% ARNI 20% 21* 21% *Standardized to 27 months, active comparator (enalapril) vs placebo JACC 2013;62:e147-239

  19. HFrEF – ACEI ACEI Doses Generic Name Trade Name Initial Daily Dose Target Dose Mean Dose Achieved in Clinical Trials Captopril Capoten 6.25mg TID 50mg TID 122.7 mg/day Enalapril Vasotec 2.5mg BID 20mg BID 16.6 mg/day Fosinopril Monopril 5 - 10mg daily 80mg daily N/A Lisinopril Zestril/ 2.5-5mg daily 20mg daily *4.5 mg/day (low dose ATLAS) Prinivil 33.2 mg/day (high dose ATLAS) Quinapril Accupril 5mg BID 80mg daily N/A Ramipril Altace 1.25 - 2.5mg daily 10mg daily N/A Trandolapril Mavik 1mg daily 4mg daily N/A *No difference between mortality between high and low dose groups, but 12% lower risk of death or hospitalization in high dose group vs. low dose group. JACC 2013;62:e147-239

  20. HFrEF – ARB ARB Doses Generic Name Trade Name Initial Daily Dose Target Dose Mean Dose Achieved in Clinical Trials Candesartan Atacand 4 -8 mg daily 32 mg daily 24 mg/day Losartan* Cozaar 12.5 - 25 mg daily 150 mg daily 129 mg/day Valsartan Diovan 40 mg BID 160 mg BID 254 mg/day *Not FDA approved for HF JACC 2013;62:e147-239

  21. ACEI/ARB: Initiation and Titration Barriers to titration ACEI/ARB • Worsening renal function • Hyperkalemia • Bilateral renal artery stenosis • Symptomatic Hypotension Select an initial dose of • Overdiuresis ACEI/ARB • Other medications Monitoring Consider increasing dose every 2 weeks • SCr and K assessed within 1-2 weeks of initiation or dose increase Monitor BP, renal function and potassium Yancy et al. JACC VOL. 71:2 ,2018

  22. What we know about RAASi dose response? Follow- Age, Male, Trial Drug Groups N up, years % months ATLAS 1 Lisinopril LD = 2.5-5.0 mg 1,596/ 64 79 46 daily 1,568 HD = 32.5-35 mg daily HEAAL 2 Losartan LD = 50 mg daily, 1,919/ 66 71 56 HD = 150 mg 1,927 daily 1. Packer M, et al. Circulation 1999;100:2312-2318 2. Konstam MA, et al. Lancet 2009;374:1840-1848

  23. Circulation. 1999;100:2312-2318

  24. Lancet 2009; 374: 1840–48

  25. ACEI/ARB with Renal Impairment Generally considered safe when: • SCr <3.0 mg/dL • Renal impairment (eGFR 30-60 mL/min/1.73m 2 ) Should we stop ACEI/ARB in CKD stage 4 and 5?

  26. Hyperkalemia: Is It Real? Pseudohyperkalemia • Delayed processing – Central vs. local labs – Traumatic draw • Presence/absence of hyperglycemia

  27. Target Serum Potassium Ranges in HF 7 • Heart Failure Hyperkalemia – 4.0-5.0 mEq/L 1,2 6 – 4.5-5.5 mEq/L 3 Serum Potassium (mEq/L) • Expert opinion 5 • Hyperkalemia Normal – 5.0 vs. 5.5 vs. 6.0 mEq/L 4 3 Hypokalemia 2 1. Circulation. 2004,110(5):588-636. 2. Arch Intern Med. 2000;160(16):2429-2436. 3. J Am Coll Cardiol. 2004;43(2):155-161.

  28. Mortality by Prior RAAS Inhibitor Dose 35 30.1 30 27.7 25 22.4 Percent of Patients 20.3 20 13.7 15 13.1 11.0 10.1 9.8 10 8.2 5.0 4.1 5 0 CKD Stage 3-4 Heart Failure Diabetes Total n = 43,288 n = 20,529 n = 79,087 n = 201,655 Maximum Dose Sub-Maximum Dose Discontinued Am J Manag Care. 2015;21:S212-S220.

  29. Clinical Dilemma Continue RAAS Inhibitor Discontinue RAAS Inhibitor Accept Hyperkalemia Sacrifice Mortality Benefit

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.


More recommend